About UQUIFA Group
UQUIFA Group is a company based in Barcelona (Spain) founded in 1936 was acquired by Vivimed Labs in December 2011. UQUIFA Group has raised $42.5 million across 2 funding rounds from investors including Orbimed, Vivimed Labs and Asian Credit Fund. The company has 28 employees as of March 23, 2024. UQUIFA Group has completed 1 acquisition, including Soneas. UQUIFA Group offers products and services including API Portfolio and CDMO Services. UQUIFA Group operates in a competitive market with competitors including Laurus Labs, Sterling Pharma Solutions, Provepharm Life Solutions, Symbiotec and Jubilant Pharma, among others.
- Headquarter Barcelona, Spain
- Employees 28 as on 23 Mar, 2024
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Uquifa India Private Limited
- Date of Incorporation 12 Jul, 2017
- Jurisdiction Hayathnagar, Telangana, India
-
Annual Revenue
$1.34 M (USD)-15.2as on Mar 31, 2023
-
Net Profit
$14.73 K (USD)114.76as on Mar 31, 2023
-
EBITDA
$43.03 K (USD)191.48as on Mar 31, 2023
-
Total Equity Funding
$42.5 M (USD)
in 2 rounds
-
Latest Funding Round
$35.75 M (USD), Debt – Conventional
Mar 10, 2025
-
Investors
Orbimed
& 2 more
-
Employee Count
28
as on Mar 23, 2024
- Investments & Acquisitions
-
Acquired by
Vivimed Labs
(Dec 01, 2011)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of UQUIFA Group
UQUIFA Group offers a comprehensive portfolio of products and services, including API Portfolio and CDMO Services.
Collection of active pharmaceutical ingredients for global use.
Contract development and manufacturing for pharmaceutical clients.
People of UQUIFA Group
Unlock access to complete
Funding Insights of UQUIFA Group
UQUIFA Group has successfully raised a total of $42.5M across 2 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $35.75 million completed in March 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Debt – Conventional — $35.8M
-
First Round
First Round
(26 Sep 2017)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2025 | Amount | Debt – Conventional - UQUIFA Group | Valuation |
investors |
|
| Sep, 2017 | Amount | Private Equity Round - UQUIFA Group | Valuation |
investors |
Investors in UQUIFA Group
UQUIFA Group has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Orbimed, Vivimed Labs and Asian Credit Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Micro credit services are provided to underserved communities in Kazakhstan.
|
Founded Year | Domain | Location | |
|
Active pharmaceutical ingredients, formulations, and specialty chemicals are manufactured.
|
Founded Year | Domain | Location |
Investments & Acquisitions by UQUIFA Group
UQUIFA Group has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Soneas.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
CDMO with expertise in olefine metathesis reactions
|
1996 |
Financial Statements - UQUIFA Group
Uquifa Group Comparisons
Competitors of UQUIFA Group
UQUIFA Group operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Laurus Labs, Sterling Pharma Solutions, Provepharm Life Solutions, Symbiotec and Jubilant Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Pharmaceutical and biotechnology company
|
|
| domain | founded_year | HQ Location |
Contract development, manufacturing, and analytical services for APIs are offered.
|
|
| domain | founded_year | HQ Location |
APIs and drug products are developed and valorized in pharmaceuticals.
|
|
| domain | founded_year | HQ Location |
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
|
|
| domain | founded_year | HQ Location |
Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company.
|
|
| domain | founded_year | HQ Location |
APIs are manufactured and custom synthesis services are provided.
|
Frequently Asked Questions about UQUIFA Group
UQUIFA Group was founded in 1936 and raised its 1st funding round 81 years after it was founded.
UQUIFA Group is headquartered in Barcelona, Spain. It is registered at Barcelona, Catalonia, Spain.
Saurabh Gurnurkar is the current CEO of UQUIFA Group.
UQUIFA Group is a funded company, having raised a total of $42.5M across 2 funding rounds to date. The company's 1st funding round was a Private Equity Round of $42.5M, raised on Sep 26, 2017.
As of Mar 23, 2024, the latest employee count at UQUIFA Group is 28.
Annual revenue of UQUIFA Group is $1.34M as on Mar 31, 2023.
UQUIFA Group was established in 1936 in Barcelona, Spain, as a CDMO in the pharmaceutical and chemical sectors. APIs and intermediates are produced to support customer programs for new chemical entities, spanning pre-clinical development through to commercial-scale manufacturing. Capabilities encompass hydrogenation, chlorination, and micronization processes, with operations centered in Europe.
UQUIFA Group's top competitors include Laurus Labs, Symbiotec and Sterling Pharma Solutions.
UQUIFA Group offers API Portfolio and CDMO Services.
UQUIFA Group has made 1 acquisition, including Soneas.
UQUIFA Group has 3 investors. Key investors include Orbimed, Vivimed Labs, and Asian Credit Fund.